Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dabur Pharma Forays Into Pak Aanti-cancer Drug Market (India)

This article was originally published in PharmAsia News

Executive Summary

Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan. "Increasingly, our focus is to expand not only in the developed markets but also in emerging ones. Recently we have started exporting our anti-cancer drugs to Pakistan," says Dabur Pharma Additional Director and Non-Executive Chairman Mohit Burman. The move follows the Pakistan government allowing imports of anti-cancer drugs from India, and the nation's health ministry has already granted permission to two companies, Atco Pharma and AJ Mirza Pharma to import from Dabur Pharma. Dabur Pharma has also started dispatches to Turkmenistan from its dosage form manufacturing unit at Baddi in Himachal Pradesh. Earlier this year, Dabur Pharma acquired the sales and distribution network of Thai firm Biosciences. Meanwhile, the company's drug Intaxel became the first ever generic oncology drug to cross 100 million Baht sales mark in the country. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066482

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel